Tags : Molecular Partners

PharmaShots Weekly Snapshot (September 09 – 13, 2019)

1. Eisai And Biogen to Terminate Two P-III Clinical Studies of Elenbecestat (E2609) for Early Alzheimer’s Disease Published: Sept 13, 2019 | Tags: Eisai, Biogen, Terminate Two, P-III, Clinical Studies, Elenbecestat, E2609, Early Alzheimer’s Disease 2. GE Healthcare’s Critical Care Suite AI-Powered X-ray Device Receives FDA’s 510(k) Clearance to Identify Pneumothorax Published: Sept 12, 2019 | Tags: […]Read More

Allergan and Molecular Partners Report Acceptance of FDA’s BLA and

Shots: The BLA and MAA are based on P-III CEDAR and SEQUOIA studies assessing Abicipar (quarterly dosing regimen) vs ranibizumab in patients with neovascular (wet) age-related macular degeneration resulting in maintaining vision gains with 6/8 vs 13 injection @52wks. with its expected approval in H2’2020 in the US & EU The acceptance of the FDA’s […]Read More

Allergan and Molecular Partners Report Result of Abicipar pegol in

Shots: The P-III MAPLE study involves assessing of abicipar pegol (2mg, q8w) in 123 patients with Neovascular Macular Degeneration (nAMD) for 28 wks. P-III MAPLE study results: 8.9% incidence of intraocular inflammation (IOI)lower than P-III studies (CEDAR and SEQUOIA); severe IOI 1.6%; no reported cases of endophthalmitis or retinal vasculitis in this study Abicipar is […]Read More

Amgen Signs an Immuno-Oncology Agreement with Molecular Partners’ for its

Shots: Molecular to receive $50M upfront, $497M milestone and royalties on sales and also has certain rights to commercialize DARPin based products with MP0310. Amgen to get exclusive worldwide development and commercialization rights for Molecular’s MP0310 The companies will jointly evaluate MP0310 with Amgen’s oncology product and BiTE (bispecific T cell engager) molecules, with defined cost sharing for first three indications Molecular’s […]Read More